Le Lézard
Classified in: Ebola virus, Transportation, Business
Subjects: ERN, ACC

Interim report, 1 January-30 June 2023


GÖTEBORG, Sweden,, Aug. 24, 2023 /PRNewswire/ -- 

Continued divestments in a strong vessel market

Events in the second quarter

Events after the end of the quarter

Key figures Jan-Jun 2023

This information is information that Concordia Maritime Aktiebolag (publ) is obliged to publish in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was provided by the contact person above for publication on 24 August 2023 at 10.00 CEST.

CONTACT:

For more information, please contact:
Erik Lewenhaupt
CEO, Concordia Maritime AB
Mob: +46 704 855 188
E-post: [email protected]

Martin Nerfeldt
CFO, Concordia Maritime AB
Tel: +45 88 938 661
Mob: +46 704 85 50 07
E-post: [email protected]

The following files are available for download:

https://mb.cision.com/Main/1948/3822896/2248242.pdf

Concordia Maritime Interim report, 1 Januaryâ?"30 June 2023 (PDF)

https://news.cision.com/concordia-maritime/i/3822896-0-png,c3208872

3822896_0.png

https://mb.cision.com/Public/1948/3822896/9ec97f6a8bcb9f98.pdf

Concordia Maritime - Press release Q2 2023 - 20230824

 

SOURCE Concordia Maritime


These press releases may also interest you

at 00:01
The two-year long slump in global private equity looks finally to be bottoming out, with the industry finding a footing from which to climb back, Bain & Company concludes...

at 00:00
Today, IXOPAY, announced the appointment of industry veteran Brady Harris as its new CEO. His appointment aligns with the recent merger of IXOPAY and TokenEx, highlighting a significant shift in the payments industry towards a multi-processor payment...

2 jun 2024
The9 Limited ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with Wuhan Weixiang Science And Technology Co., Ltd. ("WeiXiang"), an AI-powered educational technology...

2 jun 2024
Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis (AD) has been released by way of oral...

2 jun 2024
NOTICE IS HEREBY GIVEN that the 25th annual general meeting of the shareholders of GigaMedia Limited (the "Company") will be held on June 27, 2024 at 11 a.m. local time at 8F, No.22, Lane 407, Sec.2, Tiding Blvd., Neihu District, Taipei, Taiwan,...

2 jun 2024
2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the...



News published on and distributed by: